Usefulness of PTH measurements in FNAB washouts in the identification of pathological parathyroids — analysis of the factors that influence the effectiveness of this method by Popowicz, Bożena et al.
25
Prace oryginalne/original PaPers
Endokrynologia Polska
DOI: 10.5603/EP.2014.0004
Tom/Volume 65; Numer/Number 1/2014
ISSN 0423–104X
Prof. Dorota Słowińska-Klencka M.D., Ph.D., Department of Morphometry of Endocrine Glands, Chair of Endocrinology,  
Medical University of Lodz, Poland, Sterlinga St. 5, 91–425 Lodz, Poland, tel./fax: 48 42 632 25 94, e-mail: dsk@tyreo.umed.lodz.pl
Usefulness of PTH measurements in FNAB washouts  
in the identification of pathological parathyroids — analysis 
of the factors that influence the effectiveness of this method
Przydatność oznaczania stężenia PTH w popłuczynach z igły do biopsji 
aspiracyjnej cienkoigłowej w identyfikowaniu patologicznych przytarczyc  
— analiza czynników wpływających na skuteczność tej metody
Bożena Popowicz*1, Mariusz Klencki*1, Stanisław Sporny2, Joanna Jankiewicz-Wika3,  
Jan Komorowski3, Hanna Pisarek4, Dorota Słowińska-Klencka1 
*B. Popowicz and M. Klencki contributed equally to this work
1Department of Morphometry of Endocrine Glands, Chair of Endocrinology, Medical University of Lodz, Poland 
2Department of Dental Pathology, Chair of Pathology, Medical University of Lodz, Poland 
3Clinic of Endocrinology, Chair of Endocrinology, Medical University of Lodz, Poland 
4Department of Neuroendocrinology, Chair of Laboratory Diagnostics, Medical University of Lodz, Poland
Abstract
Introduction: The aim of this investigation was to assess the usefulness of the measurement of PTH concentration in the material obtained 
during FNAB (PTH-FNAB) in the identification of pathological parathyroids in patients with frequently coexisting thyroid abnormalities 
(nodular goitre, chronic thyroiditis, previous thyroidectomy). Additionally, the influence of the size of goitre, parathyroid localisation and 
size on the results of PTH-FNAB measurement was examined. 
Material and methods: Fifty patients with primary hyperparathyroidism and sonographically detected focal lesion that was suggestive of 
parathyroid gland were included in this study. PTH-FNAB results were correlated with the outcome of routine cytological examination 
and biochemical indices of hyperparathyroidism, SPECT-CT (33 patients) and histopathological examination (20 patients). 
Results: Positive PTH-FNAB was observed in 80% of patients, and in more than 70% of persons with non-diagnostic smears or smears 
‘contaminated’ with thyroid follicular cells. In the group of operated patients, sensitivity of PTH-FNAB (95.0%) was higher than SPECT-
CT (64.3%, p < 0.05). Presence of nodular goitre and/or chronic thyroiditis exerts a two times stronger negative effect on percentage of 
negative results of SPECT-CT than of PTH-FNAB. On the other hand, lower frequency of positive PTH-FNAB but not SPECT-CT was 
observed when the thickness of the thyroid was ≥ 20 mm (50% v. 87.5%, p < 0.05) and when the thickness of a lesion suspected of para-
thyroid pathology was £ 5 mm (66.7% v. 93.3%, p < 0.05). 
Conclusions: In patients with thyroid abnormalities, PTH-FNAB measurements show advantages over routine biopsy and SPECT-CT in 
the identification of typically located pathological parathyroids. (Endokrynol Pol 2014; 65 (1): 25–32)
Key words: PTH; parathyroid; FNAB; thyroid 
Streszczenie
Wstęp: Celem badania była ocena przydatności pomiaru stężenia PTH w materiale uzyskanym podczas biopsji (PTH-BAC) w identyfikacji 
patologicznych przytarczyc u pacjentów z często współistniejącymi nieprawidłowościami tarczycy (wolem guzkowym, przewlekłym 
zapaleniem tarczycy i stanem po operacji tarczycy). Dodatkowo analizowano wpływ wielkości tarczycy, lokalizacji przytarczyc i ich 
rozmiaru na skuteczność powyższej metody. 
Materiał i metody: Do badania zakwalifikowano 50 pacjentów z pierwotną nadczynnością przytarczyc i wykrytymi w USG zmianami 
ogniskowymi mogącymi odpowiadać patologicznym przytarczycom. Wyniki oceny PTH-BAC zostały skorelowane z rezultatami ruty-
nowego badania cytologicznego i biochemicznymi wskaźnikami nadczynności przytarczyc, a także wynikami SPECT-CT (33 pacjentów) 
oraz pooperacyjnego badania histopatologicznego (20 pacjentów). 
Wyniki: Dodatnie wyniki PTH-BAC stwierdzono u 80% chorych, w tym u ponad 70% osób z rozmazami niediagnostycznymi lub 
z rozmazami zawierającymi komórki pęcherzykowe tarczycy. W grupie operowanych czułość PTH-BAC była wyższa niż SPECT-CT 
(95% v. 64,3%, p < 0,05). Stwierdzono, że obecność wola guzkowego i/lub przewlekłego zapalenia tarczycy wywiera 2-krotnie silniejszy 
negatywny wpływ na odsetek ujemnych wyników SPECT-CT niż wyników PTH-BAC. Z drugiej strony, mniejszą częstość dodatnich 
wyników PTH-BAC, ale nie SPECT-CT, zaobserwowano, gdy grubość tarczycy była ≥ 20 mm (50% v. 87,5%, p < 0,05) lub gdy grubość 
zmiany podejrzanej była £ 5 mm (66,7% v. 93,3%, p < 0,05). 
Wnioski: U chorych z nieprawidłowościami morfologicznymi tarczycy ocena PTH-BAC ma przewagę nad rutynową biopsją i SPECT-CT 
w identyfikacji typowo położonych patologicznych przytarczyc. (Endokrynol Pol 2014; 65 (1): 25–32)
Słowa kluczowe: PTH; przytarczyce; BAC; tarczyca 
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Introduction
Selective surgical excision of the hyperfunctioning 
parathyroid gland is the treatment of choice in patients 
with clinically significant primary hyperparathyroidism 
(PHP) [1–2]. Therefore, preoperative localisation of 
the adenoma is critical in the evaluation of the patient 
before surgical resection. Unfortunately, there are 
significant diagnostic problems with identification of 
the glands that are the source of overproduction of 
parathormone (PTH). Ultrasound imaging (US) lacks 
necessary specificity in this respect. Scintigraphy shows 
some advantages over US, as it not only localises the 
lesion, but also allows confirmation of its parathyroid 
origin. However, thyroid nodularity and the presence 
of chronic thyroiditis lower the efficiency of both those 
examinations [3–9]. Other imaging examinations (e.g. 
computed tomography (CT), and magnetic resonance 
imaging) do not present satisfactory effectiveness either 
but significantly increase the diagnostic costs [10]. 
Better prospects are related to a combination of CT 
and scintigraphy (SPECT-CT system), which - accord-
ing to some investigators — is particularly useful in the 
diagnostics of parathyroids in patients with thyroid 
nodules [11–12]. However, this needs confirmation in 
further studies.
The routine microscopic evaluation of specimens 
obtained by fine-needle aspiration biopsy (FNAB) of 
suspected neck lesions in the majority of cases does 
not solve diagnostic doubts because of the significant 
overlap in cytomorphologic features of parathyroid and 
thyroid follicular cells [13–14]. However, it is possible to 
determine PTH in the material aspirated by means of 
FNAB. The published reports on this method are en-
couraging so far [6, 8, 9, 15–25]. But only in a few studies 
has the influence of co-existing nodular goitre on the 
discussed method been analysed [6, 8, 24]. This method 
has been applied in patients with chronic thyroiditis in 
a single report only [9]. Both mentioned disorders not 
only make it more difficult to localise pathological para-
thyroids in the extrathyroidal space but also present an 
additional need for differentiation of parathyroids from 
intrathyroid lesions in imaging studies [9, 27, 28]. The 
disorders may also influence the effectiveness of FNAB 
because of the goitre size, presence of calcifications, or 
fibrosis of the gland in the course of chronic thyroiditis 
(or as a result of radioiodine therapy). 
The aim of this investigation was to assess the use-
fulness of the measurement of PTH concentration in 
material obtained during FNAB (PTH-FNAB) in con-
firmation of the origin (parathyroid/non-parathyroid) 
of a sonographically detected lesion in patients with 
frequently coexisting thyroid abnormalities (nodular 
goitre, chronic thyroiditis, previous thyroidectomy). 
Additionally, the role was evaluated of the factors 
which can potentially influence the effectiveness of 
that method — size of goitre, parathyroid localisation 
and its size.
Material and methods
This study was performed in 2010–2012 at the Depart-
ment of Ultrasonography and Thyroid Biopsy, Uni-
versity Hospital No 2 in Lodz, Poland. The analysis 
included 50 patients with PHP (48 females and two 
males), with a focal lesion that was suggestive of 
a parathyroid gland detected in US (i.e. homogenously 
echogenic structure, usually less echogenic than the 
thyroid gland, with the presence of feeding polar vessel, 
located most commonly behind the inferior part of the 
thyroid lobe) (Fig. 1). The diagnosis of PHP was made 
on the basis of elevated PTH (with corrected vitamin D 
supply), accompanied — in the majority of patients — 
by hypercalcaemia. In nine patients, normocalcaemic 
PHP was diagnosed after the exclusion of other causes 
of elevated PTH with normal serum calcium according 
to the guidelines of the Third International Workshop 
on Asymptomatic Primary Hyperparathyroidism [29]. 
The patients were referred to US examination of the 
thyroid and parathyroid glands from the endocrine out-
patient clinic. PTH-FNAB was examined in the material 
from the lesions suspected of parathyroid origin as well 
as in the material obtained from accompanying thyroid 
nodules (internal controls — 36 lesions in 32 patients). 
In the case of thyroid nodules, FNAB was performed 
in accordance with the current recommendations on 
thyroid cytology [30–31].
PTH-FNAB results were correlated with biochemi-
cal indices of hyperparathyroidism (PTH and calcium 
serum concentration, urinary calcium excretion), the 
outcome of routine cytological examination, results of 
scintigraphic imaging (33 patients) and histopathologi-
cal examination (20 patients). Additionally, the occur-
rence of conditions associated with PHP was analysed 
(pancreatitis, nephrolithiasis, peptic ulcers, osteoporo-
sis, neuromuscular dysfunction) and the presence of 
indications for surgery (in asymptomatic patients, as 
recommended by the Third International Workshop 
on the Management of Asymptomatic Primary Hyper-
thyroidism) [29].
The influence of various factors on the efficacy of the 
PTH-FNAB method in confirming parathyroid origin 
of the suspected lesions was evaluated. That analysis 
included localisation of the suspected lesion in relation 
to the thyroid, size of the lesion, type of the coexisting 
thyroid pathology (nodular goitre, chronic thyroiditis, 
previous thyroidectomy), and the distance between 
the lesion and the skin surface. Finally, in the group 
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of operated patients, the sensitivity of PTH-FNAB was 
evaluated on the basis of postoperative histopathologi-
cal examinations. 
The study protocol was approved by the local 
bioethical committee. Written informed consent was 
obtained from each patient before participation in the 
study.
US examination
All the US examinations were performed by two 
experienced sonographers, with the use of two high-
resolution sonographs with a 7.5–14 MHz linear trans-
ducer and power Doppler capability: before September 
2011 — Siemens Elegra Advanced (Siemens Medical 
Systems Inc., Issaquah, WA, USA), and subsequently 
Aloka Prosound Alpha 7 (ALOKA Co Ltd, Tokyo, Japan). 
FNAB 
All the biopsies were US-guided. In order to obtain 
a sufficient amount of diagnostic material, usually two 
aspirations of each examined lesion were performed. 
Ten-millilitre syringes, mounted in aspirating syringe 
holders with 25 gauge (0.5 or 0.42 mm) needles, were 
used in the process. Biopsy samples were smeared onto 
glass slides for cytologic examination. Then the needle 
was immediately washed out with 1 ml of normal saline 
solution, and the collected fluid was sent to the labora-
tory for PTH determination. All the smears were fixed in 
95% ethanol and stained with haematoxylin and eosin. 
PTH, PTH-FNAB measurements
PTH levels were measured after centrifugation of fluid 
in supernatant by means of solid phase, two-site chemi-
Figure 1A. Pathological parathyroid (long arrows) in a patient with chronic thyroiditis and a thyroid nodule (short arrows). B. Pathological 
parathyroid (long arrows) in a patient with a thyroid nodule (short arrows) and an intrathyroid calcification. C. Pathological parathyroid 
(arrows) located in the posterior part of the thyroid right lobe. D. Pathological parathyroid (arrows) in a patient with chronic thyroiditis
Rycina 1A. Patologiczne zmieniona przytarczyca (długie strzałki) u pacjenta z przewlekłym zapaleniem tarczycy i zmianą 
ogniskową tarczycy (krótkie strzałki). B. Patologicznie zmieniona przytarczyca (strzałki) u pacjenta ze zmianą ogniskową tarczycy 
i wewnątrztarczycowym zwapnieniem. C. Patologicznie zmieniona przytarczyca (strzałki) zlokalizowana w tylnej części prawego płata 
tarczycy. D. Patologicznie zmieniona przytarczyca (strzałki) u pacjenta z przewlekłym zapaleniem tarczycy
A B
C D
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luminescent enzyme-labelled immunometric assay 
(IMMULITE 1000 from Siemens). The sensitivity of the 
PTH assay was 3 pg/mL (0.6 pmol/L) and the measuring 
range was 3–5,000 pg/mL. Intra-assay precision varied 
between 5.5–6.3% and inter-assay precision between 
7.9–8.6%; normal range was 10–69 pg/mL. We regarded 
PTH-FNAB samples with a value above 50 pg/mL and 
amounting to at least 20% of serum PTH concentration 
as indicative of sampling parathyroid tissue. One can 
safely assume that the residual material in a needle 
while being washed out with 1 ml of 0.9% NaCl is di-
luted at least 20 times. Thus the threshold of 50 pg/mL in 
the washout corresponds to at least 1,000 pg/mL of PTH 
in an undiluted sample. Such a value is usually found 
in pathological parathyroids, according to the report 
by Kiblut et al. [32]. An additional condition, for posi-
tive PTH-FNAB to be higher than 20% of serum PTH 
concentration, was set to secure the reliability of the 
method in patients with very high serum PTH levels.
Other laboratory examinations
Serum total-calcium was determined by fully automatic 
equipment (Roche Diagnostics Cobas Integra System 
Calcium, method according to Schwarzenbach with 
o-cresolphthalein complexone). Normal ranges were 
2.2–2.65 mmol/L for serum calcium (analytical sensitiv-
ity 0.01 mmol/L) and 2.5–8.0 mmol/d for urine calcium 
excretion on a 24-h urine collection (analytical sensitiv-
ity 0.013 mmol/L).
Scintigraphic imaging
The analysis included the outcomes of routinely per-
formed scintigraphic imaging. The examinations were 
performed at University Hospital No 2 in Lodz, Poland 
and Central Teaching Hospital in Lodz, Poland with 
single photon emission computed tomography (SPECT) 
with the use of technetium-99m (99mTc) sestamibi as 
the radiotracer, combined with X-ray based computed 
tomography (CT) — SPECT-CT. Two distinct types of 
data acquisition protocols were used. The first was 
a dual radionuclide approach with subtraction of a 99mTc 
pertechnetate image from sestamibi image; the second 
approach was sestamibi alone with early and delayed 
imaging (double-phase study). The latter imaging pro-
tocol is based on the different washout of the sestamibi 
in the thyroid and parathyroid lesions. 
Surgical treatment and histopathological  
examination
The examined patients were operated in several hos-
pitals. The bilateral exploration was performed in the 
majority of them. Because of the high incidence of 
nodular goitre, subtotal thyroidectomy was simul-
taneously performed in nearly half of the patients. 
Minimally invasive surgery was performed in some 
cases. The removed tissues were processed by standard 
procedures. If necessary, immunohistochemical exami-
nations were applied.
Statistical analysis
Continuous variables were analysed with ANOVA 
and Newman–Keuls test or if necessary with the non-
parametric Kruskal-Wallis and Mann-Whitney U tests. 
The comparison of frequency distributions was per-
formed with Chi-square test (or with Yates corrected 
Chi-square test). Correlations were assessed with the 
Pearson r coefficient. A value of 0.05 was assumed as 
the level of significance.
Results
In all the examined patients, mean serum PTH concen-
tration was 312.6 ± 395.3 pg/mL (mean ± SD), mean se-
rum Ca level was 2.81 ± 0.35 mmol/L, and mean urinary 
calcium excretion was 8.31 ± 3.54 mmol/d. Moderate 
positive correlation was found between serum PTH and 
serum Ca concentrations (r = 0.475, p < 0.05) as well as 
between serum Ca level and urinary calcium excretion 
(r = 0.341, p < 0.05).
Positive PTH-FNAB was observed in 40 patients. Table I 
shows data on the patients in relation to the result of 
PTH-FNAB. The mean positive PTH-FNAB concentra-
tion was many times higher than that observed in the 
case of negative results (p < 0.0002), as well as in the 
case of thyroid nodules – internal controls: 3.42 ± 2.19 
pg/mL ( < 3 — 5.38 pg/mL) (p < 0.0001). A weak nega-
tive correlation was noted between the patient’s age 
and PTH-FNAB concentration (r = –0.331, p < 0.05). 
Mean serum PTH and Ca concentrations as well as 
mean urinary Ca excretion did not differ significantly 
between the patients with positive and negative PTH-
FNAB results. It should be noted that the higher values 
tended to be observed in the PTH-FNAB positive group. 
Routine FNAB was positive (parathyroid cells de-
scribed in cytological outcome) in 15 cases (30.0%) of 
biopsied lesions suspected of parathyroid origin. In all 
those cases, PTH-FNAB result was also positive. High 
PTH-FNAB concentration was also observed in 25 out 
of 35 (71.4%) other biopsies, including 12 cases out of 
17 non-diagnostic FNAB (70.6%) and 13 out of 18 cases 
with thyroid follicular cells identified in cytological 
smears (72.2%). The results of FNAB of neighbouring 
thyroid nodules (internal negative control — 36 nodules 
in 32 patients) showed benign lesions in 26 (72.2%) 
cases (including chronic thyroiditis in seven patients), 
follicular lesions of undetermined significance in two 
cases (5.6%), and papillary cancer in one patient (2.8%). 
Diagnostic cellular material was not obtained from 
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seven (19.4%) nodules (three of them were partially 
cystic and mainly blood and macrophages were aspi-
rated) (Table I). 
Scintigraphy of the parathyroids was performed in 
33 (66.0%) patients. In 21 patients (63.6%), scintigraphy 
was positive and in 17 of them (81.0%) PTH-FNAB was 
positive too. Negative PTH-FNAB results in two cases 
were related to the lesions located behind the thyroid, 
deeper than 35 mm from the skin surface; in one case 
the lesion suspected of parathyroid origin was identi-
fied by ultrasound imaging in the lateral section of the 
neck in the neighbourhood of large vessels, and in 
another case the negative PTH-FNAB result was prob-
ably a consequence of the very small size of the lesion 
(its thickness equalled 4 mm). Of nine patients with 
a negative result of scintigraphy, positive PTH-FNAB 
results were observed in seven cases (77.8%). In all three 
patients with equivocal scintigraphy, PTH-FNAB was 
negative (in two cases the thickness of the suspected le-
sion was ≤ 5 mm, in all of them multiple thyroid nodules 
were present, while chronic thyroiditis was present in 
two of them) (Table I). 
No significant differences were found in the mean 
thyroid volume or its thickness between the patients 
with positive and negative PTH-FNAB, although in 
both cases higher mean values were observed in the 
PTH-FNAB negative group (Table II). Positive PTH-
FNAB results were noted in 25 out of 32 (78.1%) cases 
of suspected lesions located behind the thyroid gland, 
in 14 out of 16 (87.5%, NS) cases of lesions located be-
low the lower pole of the thyroid lobe, and in one case 
of intrathyroidal lesion. In the case of lesions located 
behind the thyroid, the higher frequency of negative 
PTH-FNAB was observed when the thyroid thickness 
was ≥ 20 mm compared to the thyroid thickness < 20 mm 
50.0% (4/8 cases) v. 12.5% (3/24 cases), (p < 0.05). Similar 
relations were not observed between the patients with 
positive and negative scintiscans.
No significant differences were found between le-
sions with positive and negative PTH-FNAB in terms 
of either their volume or thickness (Table II). However, 
after the exclusion from the analysis of three cases 
which — because of goitre and adipose tissue — were 
located deeper than 35 mm from the skin surface, 
a marked decrease in the mean volume and thickness 
of PTH-FNAB negative lesions was noted — to the level 
observed in the cases with negative scintigraphy. After 
that exclusion, a moderate positive correlation between 
Table I. Data on age, laboratory findings, outcomes of routine FNAB and scintigraphy of the patients with positive and 
negative PTH-FNAB results
Tabela I. Dane dotyczące wieku, rezultatów badań laboratoryjnych oraz rutynowej BAC i scyntygrafii u pacjentów z dodatnimi 
i ujemnymi wynikami oceny PTH-BAC
PTH-FNAB positive PTH-FNAB negative
No/% of patients 40/80.0 10/20.0
Age, mean ± SD 59.5 ± 11.5 70.0 ± 8.9a
Min–Max 30–88 50–64
PTH-FNAB [pg/mL], mean ± SD 2,822.4 ± 2,061.3 12.3 ± 8.7b
Min–max 72.7–> 5,000.0 < 3.00–21.1
Serum PTH [pg/mL], mean ± SD 333.5 ± 428.3 220.4 ± 196.9
Min–max 70.0–1,852.0 92.9–744.8
Serum Ca [mmol/L], mean ± SD 2.8 ± 0.4 2.8 ± 0.2
Min–max 2.5–4.6 2.5–3.0
Urine Ca [mmol/d], mean ± SD 8.4 ± 3.6 8.2 ± 3.4
Min–max 2.5–20.0 3.1–12.0
No/% of patients with diagnostic FNAB 28/70.0 5/50.0
No/% of patients with positive FNAB 15/53.4 0/0.0
No/% of patients with non-diagnostics FNAB 12/30.0 5/50.0
No/% of patients with scintigraphy 24/60.0 9/90.0
No/% of patients with positive scintigraphy 17/70.8 4/44.4
No/% of patients with equivocal scintigraphy 0/0.0 3/33.3
No/% of patients with negative scintigraphy 7/29.2 2/22.2
No/% of patients with surgical treatment 19/47.5 1/10.0
ap < 0.01; bp < 0.0002
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PTH-FNAB concentration and the volume (r = 0.304, 
p < 0.05) and thickness of the examined lesion was 
noted (r = 0.359, p < 0.05). It was also found that the 
frequency of negative PTH-FNAB results was higher in 
the case of lesions of thickness £ 5 mm when compared 
to the lesions of thickness above 5 mm: 35.3% (6/17) v. 
6.7% (2/30), p < 0.05. A similar relation was not found 
in respect to scintigraphic examination - negative re-
sults were observed in 46.2% (6/13) of lesions of which 
thickness was £ 5 mm and in 30.0% (6/20) of lesions of 
which thickness was above 5 mm (NS). 
In general, negative PTH-FNAB results and negative 
SPECT-CT outcomes were observed, with increasing 
frequency, in patients with nodular goitre, chronic 
thyroiditis and with both abnormalities coexisting, but 
this effect was more distinct for scintigraphic examina-
tion (Table II). 
Indications for surgical treatment were found in 
41 patients. Signs or symptoms of PHP occurred in 
38 (76.0%) patients (osteoporosis was the most frequent 
finding — in 30 patients). In two patients, the only in-
dication for surgery was serum Ca, and in another one 
it was serum Ca and age. However, parathyroid surgery 
was performed in 20 patients only (including 14 patients 
with scintigraphy results available). The other patients 
had contraindications to surgical treatment or did not 
give their consent. In all the operated patients, the pres-
ence of pathological parathyroids was confirmed: para-
thyroid hyperplasia in five (25.0%) patients, adenoma in 
14 (70.0%), and cancer — of intrathyroidal location - in 
one (5.0%). No false positive (FP) or TN results were 
observed for any of the analysed methods in relation 
to histopathological examination and only their sensi-
tivity was determined. It was found that sensitivity of 
PTH-FNAB amounted to 95.0% (19/20) and was higher 
than that of scintigraphy — 64.3% (9/14), p < 0.05, and 
of routine cytological examination — 40.0% (8/20), 
p < 0.001. There were no significant differences in the 
mean PTH-FNAB concentration between the patients 
with parathyroid adenoma and parathyroid hyperpla-
sia (3,428.8 ± 2,285.5 pg/mL v. 2,758.4 ± 2,063.6 pg/mL). 
Discussion
Our results confirm that examination of PTH concen-
tration in aspirated material is an effective method for 
establishing the parathyroid origin of cervical lesions 
detected sonographically. PTH-FNAB measurements 
showed significant advantage in relation to classical 
cytological examination. This method allows positive 
outcomes to be obtained even when aspirated material 
is scarce or it is contaminated with thyroid follicular cells 
from the needle tract (in our material, PTH-FNAB was 
positive in above 70.0% of non-diagnostic or confusing 
smears). Usually, it is not possible to clearly distinguish 
these cells from the parathyroid gland cells, which 
has been indicated by many investigators [13–14]. In 
the presented study, the routine FNAB allowed us to 
diagnose parathyroid tissue in 30% of cases. That value 
is similar to data reported by Bancos et al. [20] — 31% 
— and is higher than that showed by Giusti et al. [8] — 
17%. The relatively high percentage of non-diagnostic 
Table II. Comparison of the thyroid size, the size of focal lesion suggestive of pathological parathyroid, and the presence of 
thyroid abnormalities in patients with positive and negative results of PTH-FNAB and SPECT-CT
Tabela II. Porównanie rozmiarów tarczycy i rozmiarów ognisk mogących odpowiadać przytarczycom oraz obecności 
nieprawidłowości morfologicznych tarczycy u pacjentów z dodatnimi i ujemnymi wynikami oceny PTH-BAC i SPECT-CT
PTH-FNAB SPECT-CT
Positive Negative Positive Negative
Mean thyroid volume ± SD [cm3] 15.7 ± 12.3 19.6 ± 14.9 17.1 ± 14.7 14.1 ± 4.3
Mean thyroid thickness ± SD [mm] 15.7 ± 5.3 18.3 ± 4.8 15.2 ± 6.2 16.1 ± 3.1
Mean volume of PTH lesion ± SD [mm3] 0.808 ± 1.450 
(0.821 ± 1.473#)
1.115 ± 2.175 
(0.314 ± 0.378#)
0.906 ± 1.502 0.292 ± 0.189
Mean thickness of PTH lesion ± SD [mm] 8.05 ± 3.09 
(8.13 ± 4.01#)
8.10 ± 6.05 
(5.62 ± 3.46#)
8.4 ± 4.5 6.2 ± 2.6
No/% of examined patients 40/80.0 10/20.0 21/63.6.0 12/36.4.0
No/% of patients without thyroid abnormalities 4/100.0 0/0.0 3/75.0 1/25.0
No/% of patients with previous thyroidectomy 3/100.0 0/0.0 1/100.0 0/0.0
No/% of patients with thyroid nodules 26/76.5 8/23.5 13/59.1 9/40.9
No/% of patients with chronic thyroiditis 17/73.9 6/26.1 7/46.7 8/53.3
No/% of patients with thyroid nodules and chronic thyroiditis 10/71.4 4/28.6 3/33.3 6/66.7
#lesions located deeper than 35 mm were excluded 
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smears from parathyroid lesions is not surprising either. 
This could be related to the difficult location of such 
lesions, especially in patients with goitre. In reports 
from other centres, the observed percentage of non-
diagnostic cytological examinations of parathyroids 
was also high [14]. Particularly difficult conditions for 
aspirating the proper material — also for PTH-FNAB 
determination – occur, according to our observations, 
when the lesion is very small (thickness < 5 mm), or 
when it is deeply located (especially above 35 mm from 
the skin surface) or when it is located in proximity to 
large neck vessels. Additionally, when parathyroid is 
located behind thyroid lobe it is significant if the thick-
ness of the thyroid is above 20 mm.
Our data showed that PTH-FNAB measurements 
have some advantages over the SPECT-CT in the 
identification of parathyroids in patients with nodular 
goitre and/or chronic thyroiditis. Sensitivity of PTH-
FNAB measurements is higher than that of scintigraphy 
(95.0% v. 64.3%). Moreover, PTH-FNAB allowed us to 
confirm parathyroid origin of nearly 80% of lesions 
with negative scintiscans. It is the case, in spite of the 
fact that SPECT-C is especially useful in patients with 
nodular goitre. 
Our results indicated that both nodular goitre and 
chronic thyroiditis affect the effectiveness of scintig-
raphy more than that of the PTH-FNAB method. The 
negative influence of the presence of thyroid nodules 
on both methods has already been described [6, 8–9, 24]. 
An unfavourable effect of coexisting chronic thyroiditis 
on scintigraphy has been recently reported by Boi et al. 
[9]. However, the authors noticed the negative effect of 
chronic thyroiditis on the effectiveness of scintigraphy 
only, and did not find any negative influence of thyroid 
abnormalities on parathyroids identification with the 
use of PTH-FNAB. This difference may be due to the 
fact that Boi et al. examined parathyroids of markedly 
larger sizes [9].
It should be stressed that there is no established 
standard as to what level of PTH-FNAB should be 
regarded as evidence that the aspirated tissue repre-
sents parathyroid tissue. Some investigators assume 
PTH-FNAB to be positive when the result is higher 
than the normal range on their assay [25], while others 
do so when it is higher than serum PTH concentration 
[26]. Obviously the applied limit depends on whether 
PTH-FNAB concentration is determined in the diluted 
material or directly. If the aspirate is rinsed and diluted, 
the measured PTH-FNAB level probably corresponds 
to a much higher concentration in the original sample. 
Usually a needle is flushed with 0.5–1 mL of fluid 
(0.9% NaCl, serum or other). Thus, in the comparison 
with determination in the serum, such a sample is 
diluted at least 10–20 times before assay. Therefore, 
clearly detectable PTH in the aspirate, even if it does 
not exceed the corresponding circulating level, can be 
considered as indicative of the parathyroid nature of the 
aspirated mass. However, in all the cases, we observed 
PTH-FNAB concentrations to be either higher than 
serum PTH concentrations (frequently elevated into 
the hundreds or thousands of pg/mL) or very low if 
not undetectable, doubtlessly negative. Similarly, other 
reports have indicated that PTH level in the aspirate 
is rarely equivocal [6, 8–9, 24]. Blood contamination in 
biopsies of non-parathyroid lesions may explain the 
small amounts of PTH detected in negative aspirates 
[15]. Our data did not show any differences in PTH-
FNAB concentrations between hyperplastic lesions and 
parathyroid neoplasms. Similar observations have been 
reported by others [32–33]. 
We did not observe any complications after FNAB 
of parathyroid lesions, nor were they mentioned in 
postoperative histopathological reports. Similar ob-
servations were reported by Kendrick et al. [34]. It 
should be mentioned that during the FNAB procedure 
we performed at the most two punctures. A relation 
between the number of punctures and the occurrence 
of complications has been shown for the FNAB of the 
thyroid gland [35], and it is also very probable for the 
FNAB of the parathyroids. 
A weakness of our study is the lack of postop-
erative histopathological verification in all examined 
patients, which along with biochemical normalisation 
after surgery is the best confirmation of the proper 
localisation of pathological parathyroid gland. Some 
patients did not give their consent to surgical treat-
ment despite the indications to such treatment and 
positive PTH-FNAB, routine FNAB or scintiscans. In 
some patients, there were also contraindications to 
surgery. Others did not satisfy the current criteria for 
surgical treatment and were treated conservatively. 
With missing histopathological examination, we were 
unable to exclude if negative PTH-FNAB result in the 
case of negative or equivocal scintiscans and routine 
FNAB was a consequence of wrong interpretation of US 
images or some mistake during the aspiration. On the 
other hand, it should be stressed that limitation of the 
analysed series of patients to the operated ones does not 
reflect the clinical spectrum of patients diagnosed for 
PHP. So, such selection of patients could be the source 
of significant bias.
 Summing up, in our series the incidence of thy-
roid abnormalities was very high — above 90%. In 
this group of patients, the PTH-FNAB measurements 
showed advantages in the relation to routine biopsy 
and SPECT-CT in identification of typically located 
pathological parathyroids. This method does not rely 
on any additional puncture and practically brings no 
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risk of false positive results nor risk of complications 
(provided the number of punctures is low). The main 
limitation of PTH-FNAB measurements is the need to 
initially identify a potential parathyroid lesion by US. 
False negative results of this method may also occur if 
there are technical difficulties in performing a biopsy 
— in the cases of very small lesions or when a lesion’s 
location is difficult to access with a biopsy needle. 
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